FILTER

Refine your search with the following facets to narrow down your results.

8,623 Current news from the industry pharma

Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu

23-Feb-2006 - Novartis and Alnylam Pharmaceuticals, Inc. announced that they have formed a new collaboration to develop RNAi therapeutics for pandemic flu. This collaboration is in addition to the collaboration formed by the two companies in September 2005, and significantly reinforces the development program ...

Alnylam Novartis pandemic influenza +1

Cipher receives Health Canada approval of CIP-Fenofibrate

22-Feb-2006 - Cipher Pharmaceuticals Inc. announced that it has received final approval from Health Canada for CIP-Fenofibrate, the Company's novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. Health Canada has issued a Notice of Compliance for ...

food

Cryptome completes acquisition of HealthLinx

21-Feb-2006 - Cryptome Pharmaceuticals Limited announced that it has completed the acquisition of HealthLinx Pty Ltd. HealthLinx, a privately held company before its acquisition, focuses on Biomarkers and the development of diagnostics, with its lead candidates targeting ovarian cancer and complications in ...

bases biomarkers Dairy +2

Alkermes Announced Submission of Complete Response to FDA for VIVITROL New Drug Application

21-Feb-2006 - Alkermes, Inc. announced the submission of a complete response to the approvable letter issued in December 2005 by the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for VIVITROL(TM) (naltrexone for extended-release injectable suspension). Alkermes expects the ...

food

European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody

17-Feb-2006 - GPC Biotech AG announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended the granting of orphan medicinal product designation for the anticancer monoclonal antibody 1D09C3 for the treatment of multiple myeloma. The orphan drug status ...

chronic lymphocytic leukemia GPC Biotech Hodgkin lymphoma +4

Acambis announces results from Phase 1 trial of C. difficile vaccine

17-Feb-2006 - Acambis plc announced results from a Phase 1 trial of its investigational vaccine against Clostridium difficile (C. difficile) in healthy adults. Acambis' Phase 1 trial evaluated the safety, tolerability and immunogenicity of its C. difficile vaccine when administered at different dose levels. ...

Clostridium difficile immunogenicity pain +1

Bharat Biotech & Partners develop an indegenous rotavirus vaccine

17-Feb-2006 - The Indian Rotavirus Vaccine Development Project (RVDP) announced encouraging results from a recent Phase I clinical trial of two live, natural reassortant, candidate rotavirus vaccines, 116E and I321, conducted in New Delhi, India. The RVDP consisting of the Department of Biotechnology (Govt. of ...

clinical trials diarrhea quality control +2

Evotec and Apeiron Biologics to Discover Novel Pain Therapeutics

17-Feb-2006 - Evotec AG and Apeiron Biologics GmbH announced that they have entered into a discovery collaboration to develop small molecules targeting a novel therapeutic concept for pain relief. This concept is based on research activities of Prof Josef Penninger, Director of the Institute for Molecular ...

Evotec pain

Cerus Obtains Exclusive Rights to INTERCEPT Blood System from Baxter

15-Feb-2006 - Cerus Corporation and subsidiaries of Baxter International Inc. announced that they have entered into a definitive agreement for Cerus to obtain Baxter¡¦s remaining commercial rights to the INTERCEPT· Blood System for platelets and plasma effective February 1, 2006. Cerus now has exclusive ...

Baxter China diseases +7

Geron and Cambrex Announce Contract Manufacturing Arrangement for cGMP Production of GRNVAC1 for Clinical Trials

15-Feb-2006 - Geron Corporation and Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, announced an agreement for the manufacture of Geron's GRNVAC1 telomerase vaccine. The agreement provides for the transfer of Geron's vaccine production process to Cambrex and the cGMP manufacture of ...

clinical trials dendritic cells immunology +4